• No results found

CURRICULUM VITAE. Doctor of Medicine, The Johns Hopkins University School of Medicine Baltimore, Maryland

N/A
N/A
Protected

Academic year: 2021

Share "CURRICULUM VITAE. Doctor of Medicine, The Johns Hopkins University School of Medicine Baltimore, Maryland"

Copied!
48
0
0

Loading.... (view fulltext now)

Full text

(1)

Kuldev Singh, M.D., M.P.H.

Professor of Ophthalmology

Director, Glaucoma Service

Stanford University School of Medicine

Department of Ophthalmology

2452 Watson Court

Palo Alto, CA 94303

Phone:

Fax:

E-mail:

_

_____________________________________________________________

Personal Facts

Birthplace: Birthdate: Citizenship: Spouse: Daughter:

Education

Master of Public Health, The Johns Hopkins University, School of Hygiene and Public Health, Department of Epidemiology, Baltimore, Maryland

Doctor of Medicine, The Johns Hopkins University School of Medicine Baltimore, Maryland

Bachelor of Science, McGill University, Montreal, Canada, Double major in Biology and Economics

(2)

Page 2 of 48

Postdoctoral Training:

Fellow, Glaucoma Service, Bascom Palmer Eye Institute, Anne Bates Leach Eye Hospital University of Miami School of Medicine, Miami, Florida (

Resident, Ophthalmology, Casey Eye Institute

Oregon Health and Science University, Portland, Oregon ( )

Intern, Department of Internal Medicine, Greater Baltimore Medical Center Baltimore, Maryland

Eleanor Naylor Dana Charitable Trust Fellow in Preventive Ophthalmology Dana Center for Preventive Ophthalmology, Wilmer Eye Institute

The Johns Hopkins University, Baltimore, Maryland ( )

Honors and Awards

World Glaucoma Association Founder’s Award: one of two recipients of the 2013 award and the seventh recipient in the 10 year history of the Association

Asian American Faculty Award, Stanford University: one of two recipients of university-wide award

Glaucoma Speaker Award, Royal Hawaiian Eye Meeting Secretariat Award, American Academy of Ophthalmology

Franklin G. Ebaugh Jr. Award for Advising Medical Students, Stanford University School of Medicine: sole recipient of medical school-wide award (

Secretariat Award, American Academy of Ophthalmology

First Prize: Challenge Cup, American Society of Cataract and Refractive Surgery Annual Meeting

Senior Achievement Award: American Academy of Ophthalmology Glaucoma Speaker Award, Royal Hawaiian Eye Meeting

Achievement Award: American Academy of Ophthalmology Best Doctors in America

(3)

Page 3 of 48

Dana Fellowship, The Johns Hopkins University ( ) Graduation with Great Distinction, McGill University ( Faculty Scholar, McGill University (

James McGill Award, McGill University (

Professional Organizations:

• American Academy of Ophthalmology

• American Glaucoma Society

• American Society of Cataract and Refractive Surgery

• Association for Research in Vision and Ophthalmology

• Bridgeport Glaucoma Society

• International Council of Ophthalmology

• Johns Hopkins Medical and Surgical Association

• Pan American Glaucoma Society

• Peninsula Eye Society

• Unite for Sight

• World Glaucoma Association

Board Certification

American Board of Ophthalmology, Initial Certification: Recertified: Recertified:

Licensure

California - Current: Oregon ( )

Academic Appointments

Professor of Ophthalmology, Stanford University Stanford, CA (2003-present)

Academic Advising Dean, Stanford University Stanford, CA (2002-2005)

Associate Professor of Ophthalmology, Stanford University Stanford, CA (1998-2003)

(4)

Page 4 of 48

Assistant Professor of Ophthalmology, Stanford University Stanford, CA (1992-1998)

Director, Glaucoma Service, Stanford University Stanford, CA (1992-present)

Hospital Appointments

Stanford University Medical Center Stanford, CA (1992-present)

Veterans Administration Medical Center Palo Alto, CA (1992-2008)

Lucille Salter Packard Children’s Hospital at Stanford Stanford, CA (1992-present)

Major Leadership Positions in National and International Organizations

President, American Glaucoma Society, 2013-

Executive Vice President, World Glaucoma Association (2008-2012) Chair, Board of Directors, Glaucoma Research Foundation (2009-2011)

Other Administrative and Leadership Appointments

Board of Directors, Pan American Glaucoma Society, 2011- Chair, Ethics Task Force, American Glaucoma Society, 2011-

Chair, Glaucoma Subspecialty Day Program Committee, American Academy of Ophthalmology, 2011-

Special Government Employee-Consultant, United States Food and Drug Administration, 2011-

Member, American Academy of Ophthalmology Patient Education Committee, 2010- Chair, Patient Care Committee, American Glaucoma Society (January 1, 2008-2011)

(5)

Page 5 of 48

Strategic Planning Committee, American Glaucoma Society, 2008- Board of Directors, Glaucoma Research Foundation, 2007-2013

Medical Advisory Board, Unite for Sight, 2007-

Board of Governors, World Glaucoma Association, 2007-

Co-chair, Guidelines Task Force. American Glaucoma Society (2007-2008) Chair, Document Review Subcommittee of the Patient Care Committee. American Glaucoma Society (2007-2008)

Media Advisory Committee, American Academy of Ophthalmology, 2006 Elected At-Large Member, Faculty Senate of the Stanford University School of Medicine (2006-2009), re-elected for second term (2009-2012)

Invited Nominator for Nobel Prize for Physiology and Medicine. Nobelkom Karolinska Institute, Stockholm Sweden (six annual invitations since 2005)

Member, Executive Committee, American Glaucoma Society (2004-2007, 2011-) Member, Board of Directors, American Glaucoma Society, 2004-

Chair, Ophthalmic Technology Assessment Committee Glaucoma Panel, American Academy of Ophthalmology (2003-2009)

Member, Steering Committee, World Glaucoma Association (2002-2007) Member, Program Planning Committee, Glaucoma Subspecialty Day,

American Academy of Ophthalmology (2002-2007, 2011-) co-chair (2002-2003, 2011-) Co-Chair, Committee on Meetings, World Glaucoma Association (2002-2007)

Member, Nominating Committee, American Glaucoma Society (2002-2005) Member, Human Subjects Panel for Non-Medical Research

Stanford University School of Medicine (2001-2002)

Member, Research Committee, American Glaucoma Society (2000-2005) Media Spokesperson, American Academy of Ophthalmology, 2000-

Methodologist, Ophthalmic Technology Assessment Committee Glaucoma Panel American Academy of Ophthalmology, 1999-)

(6)

Page 6 of 48

Member, American Glaucoma Society and American Academy of Ophthalmology Committee on Terminology and Coding (1998-1999 )

Acting Chairman (3 months)

Department of Ophthalmology, Stanford University School of Medicine (1995) Member Ophthalmic Instruments and Maintenance Subcommittee of the Committee on International Ophthalmology

American Academy of Ophthalmology (1995) Acting Member, Faculty Senate

Stanford University School of Medicine (1995-1996) Advisor, First Year Medical Students

Stanford University (1993-1999) Undergraduate Freshman Advisor Stanford University (1993-1997) Member

Stanford University Hospital Quality of Care Committee (1993) Director, Ophthalmic Education of Internal Medicine Residents Stanford University (1993-1996)

Director, Ophthalmology Residency Training Program Stanford University School of Medicine (1993-1996) Member, Admissions Panel

Stanford University School of Medicine (1992-2007)

Participation in Competitively Funded Research

National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) Investigator at Stanford site (2009-present)

Principal Investigator of National Study: Janey Wiggs MD PhD National Eye Institute HG005259-01

Tube versus Trabeculectomy Study National Eye Institute: EY014801

Research to Prevent Blindness (1999-present) Principal Investigator: Steven Gedde, MD

(7)

Page 7 of 48

with several funded by Research to Prevent Blindness (1997-present), Principal Investigator: Kuldev Singh MD MPH

Baltimore Eye Survey, National Eye Institute EY-05091 National Institutes of Health RR-04060 (1986-1992) Principal Investigator: Alfred Sommer MD MHS

Also supported by NIH-NEI Core Grant EY002162 for Vision Research and NIH/NCRR/OD UCSF-CTSI Grant Number TL1RR024129.

Presentations and Visiting Professorships: (230)

Invited Speaker, Sydney Eye Hospital. Landmark Glaucoma Trials: What We Have and Have Not Learned. Sydney, Australia. August 2, 2013.

Invited Speaker, Session Chair and Course Moderator, World Glaucoma Congress. (1) Current Controversies in Glaucoma. (2) Glaucoma and Myopia. (3) Individualized Patient Considerations in the Acceleration of Therapy. Vancouver, Canada. July 17-20th, 2013 Invited Speaker, Masters in Ophthalmology 2013, Florida Society of Ophthalmology Annual Meeting (1) Landmark Glaucoma Trials: What We Have and Have Not Learned (2) Normal Tension Glaucoma: Is it a Different Disease? (3) Glaucoma Surgery With and Without Cataract Surgery: Evolution versus Revolution. West Palm Beach, Florida. June 27th-29th, 2013

Invited Keynote Speaker, Slovak Glaucoma Society (1) Evolution of Traditional Glaucoma Surgery (2) Revolution in Combined Cataract and Glaucoma Surgery. Kosice, Slovakia April 26-27, 2013.

Invited Speaker, American Society of Cataract and Refractive Surgery (1) Featured Lecture on Glaucoma Day: Timely Cataract Surgery for Optimal Glaucoma Management (2) Fifteen Pearls for Limbal Based Trabeculectomy Closure (3) Does Glaucoma Change the Indication for Cataract Surgery? San Francisco, CA. April 19-21, 2013.

Invited Speaker, American Glaucoma Society Annual Meeting. (1) Co-moderator, Glaucoma Practitioner, Academic and State Affairs (2) Limitations of Target IOP (3) Introduction of the keynote American Glaucoma Society Lecture. San Francisco, CA. March 1, 2013.

Invited Speaker, University of California, San Diego. Is Cataract Surgery Treatment for Glaucoma? La Jolla, CA. February 16, 2013.

Invited Speaker, Glaucoma Research and Education Meeting. Should Cataract Surgery Be Considered a Glaucoma Procedure. San Francisco, CA. February 2, 2013.

Invited Speaker, New Orleans Academy of Ophthalmology, 62th Annual Symposium. (1) Should Writing a Target IOP in the Medical Record be Necessary for Glaucoma Practice?

(8)

Page 8 of 48

(2) Landmark Glaucoma Trials: What We Have and Have Not Learned (3) Timely Cataract Surgery for Optimal Glaucoma Management, January 25-27, 2013.

Invited Keynote Speaker, 16th Annual Rotterdam Glaucoma Symposium for Benelux Countries. (1) The Landmark Glaucoma Trials: What We Have and Have Not Learned (2) Glaucoma Surgery With and Without Cataract Surgery: Evolution versus Revolution. Rotterdam, The Netherlands, January 12, 2013.

Visiting Professor, Georgetown University School of Medicine. (1) Randomized Clinical Trials: What We Have and Have Not Learned (2) Glaucoma Surgery With and Without Cataract Surgery: Evolution versus Revolution. Washington D.C., October 16, 2012. Visiting Professor, Albert Einstein College of Medicine, Montefiore Medical Center. Should Cataract Surgery be Considered a Glaucoma Procedure? Bronx, NY, October 15, 2012.

Visiting Professor, University of North Carolina School of Medicine. (1) Randomized Clinical Trials: What We Have and Have Not Learned (2) Glaucoma Surgery With and Without Cataract Surgery: Evolution versus Revolution. Chapel Hill, NC, October 13, 2012.

19th Annual Roger P. Mason Sr. Memorial Lecture, Howard University. Antifibrotic Use with Primary Trabeculectomy. Washington D.C., September 21, 2012

Invited Speaker, International Congress on Glaucoma Surgery. (1) WGA Guidelines for Glaucoma Surgery (2) Moderator, Outcomes and Controversies (3) Chair, Surgical Techniques/New Technologies. Glasgow, Scotland. September 13, 2012.

Invited Speaker, European Society of Cataract and Refractive Surgery: Glaucoma Day. The Effect of Phacoemulsification on IOP in Patients with Primary Angle Closure Glaucoma. Milan, Italy. September 7, 2012.

Co-Chair, Ophthalmology Futures 2012. Moderator, Glaucoma Surgical Innovation: The Present and the Future. Milan, Italy. September 6, 2012.

Invited Speaker, European Glaucoma Society. Glaucoma Care in the Developing World. June 19, 2012. Copenhagen, Denmark. June 19, 2012.

Invited Keynote Speaker, Lithuanian Glaucoma Society. (1) Cataract Surgery With or Without Glaucoma Surgery: Evolution vs Revolution. (2) Myopia and Glaucoma.

Invited speaker, American Society of Cataract and Refractive Surgery Glaucoma Day. The Real World: When Do I Go Trab or Go to Tube. Chicago, IL April 20, 2012.

Invited Speaker, American Glaucoma Society Annual Meeting. New York, NY February 29-March 1, 2012.

(9)

Page 9 of 48

Invited Speaker, North Shore Long Island Jewish Hospital. Glaucoma Surgery With or Without Cataract Surgery: Evolution vs Revolution. Great Neck, NY. February 1, 2012. Invited Speaker, Moorfields International Glaucoma Symposium. (1) Glaucoma

Demographics and Patient Numbers. (2) Will Trabeculectomy Be Dead in 5 years? (3) Panelist, Dragon’s Den Grand Rounds. London, United Kingdom. January 27-29, 2012. Invited Speaker, Royal Hawaiian Eye Meeting. (1) Is Cataract Surgery Glaucoma Surgery? (2) Glaucoma Surgery With and Without Cataract Surgery: Evolution vs Revolution. (3) Should Pre-Perimetric Glaucoma Be Treated with IOP Lowering Therapy? Wailea, HI. January 15-19,, 2012.

Invited Speaker, U.S. Food and Drug Administration. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. Silver Spring, MD. December 13, 2011.

Invited Speaker, World Glaucoma Congress. (1) Blood Pressure, Perfusion Pressure and IOP Fluctuation: Should They Be Treated? (2) Glaucomatous Disease in Young Chinese Myopes (3) Trabeculectomy (4) Video Symposium: Combined Phacoemulsification, Posterior Chamber IOL Implantation and Mitomycin C Trabeculectomy. Paris, France. June 29-July 2, 2011.

Invited Speaker, Arizona Ophthalmological Society. (1) Is Setting a Target IOP Necessary in Glaucoma Practice (2) Is Phacoemulsification the Best Glaucoma Surgical Procedure? Flagstaff, AZ. May 20-22, 2011.

Invited Keynote Speaker, Glaucoma Society of France. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. Paris, France May 7, 2011. Invited Speaker, Glaucoma Day at the American Society of Cataract and Refractive Surgery Annual Meeting. Trabeculectomy. San Diego, CA. March 25th, 2011.

Invited Speaker, Moderator and Introducer of Keynote Glaucoma Surgery Day Lecture. American Glaucoma Society Annual Meeting. Dana Point, CA. March 3, 2011.

Invited Speaker, Glaucoma Research and Education Meeting. What Comes After a Failed Trabeculectomy: Lessons From the TVT Study. San Francisco, CA. February 4, 2011. Invited Speaker, Hawaiian Eye Meeting. (1) Glaucoma Practice Without Setting a Target IOP. (2) Should Laser Trabeculoplasty be the First Step in Glaucoma Therapy? Kaanapali, HI. January 19, 2011.

Visiting Professor, University of Kentucky. (1) Intraocular Pressure and Primary Open Angle Glaucoma: What We Have Learned From Randomized Clinical Trials. (2) Is Setting a Target IOP Necessary in Glaucoma Practice? Lexington, KY. December 3, 2010.

(10)

Page 10 of 48

2010 President’s Award Lectures, Optometric Glaucoma Society (Research) Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned and Normal Tension Glaucoma: Is it a Different Disease? San Francisco, CA. November 16-17, 2010.

Daniel Scott Weston Lecture, Glaucoma Research Foundation. Glaucoma Surgery: When Should We Expect a Breakthrough? San Francisco, CA. October 7, 2010.

Keynote Speaker, Retina Update 2010. What to Do Next After the First Trabeculectomy Fails: Lessons from the Tube versus Trabeculectomy Study. Sacramento, CA. September 25, 2010.

Invited Speaker, University of California San Francisco Glaucoma Update 2010. What Causes Glaucoma IV: Epidemiology. Napa, CA. September 24, 2010.

Invited Speaker, European Glaucoma Society (1) Glaucoma Care in Developing Countries. (2) Target Pressure and Target Function in Long Term Glaucoma Management. Madrid, Spain. September 13-16, 2010.

Invited Speaker, 94th Annual Meeting of the Pacific Coast Oto-Ophthalmological Society. Is Phacoemulsification the Best Glaucoma Operation? Aptos, CA. June 25-29, 2010. Invited Speaker, World Ophthalmology Congress (1) What is Done Now for Open Angle Glaucoma in the Developing World. (2) Tube versus Trabeculectomy and Other Studies. Berlin, Germany. June 5-9, 2010.

Invited Speaker, State University of New York Downstate Medical Center. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. Brooklyn, NY. June 3, 2010.

Invited Speaker, Scientific Symposium: Glaucoma Management: Beyond Intraocular Pressure. Intraocular Pressure Parameters: Do We Know What Counts. San Diego, CA. May 8, 2010.

Invited Speaker, American Glaucoma Society Annual Meeting (1) Primary Surgery: MMC vs 5-FU. (2) What Intraocular Pressure Parameters are Important in Clinical Practice? Naples, FL. March 3-7, 2010.

Invited Speaker, New Orleans Academy of Ophthalmology, 59th Annual Symposium. (1) Normal Tension Glaucoma, Is It a Different Disease. (2) Randomized Clinical Trials in Glaucoma. (3) Target IOP in Glaucoma Practice. (4) Should Laser Trabeculoplasty be Initial Glaucoma Surgery. (5) What to do Next After the First Trabeculectomy Fails: Lessons from the TVT Study. New Orleans, LA. February 5-7, 2010.

Invited Speaker, The Royal Hawaiian Eye Meeting. (1) The IOP-Glaucoma Relationship: Myth vs Reality. (2) IOP Fluctuation: How Much Does it Matter? Poipu, HI. January 18-20, 2010.

(11)

Page 11 of 48

Invited Speaker, Inaugural Zimmerman Glaucoma Symposium, University of Louisville. Is Cataract Surgery the Best Glaucoma Operation? Louisville, KY. October 17, 2009. Invited Speaker, Glaucoma Research Foundation. Glaucoma: A National Imperative. Belvedere, CA. September 23, 2009.

Invited Speaker/Chair World Glaucoma Congress of the World Glaucoma Association (1) Aqueous Drainage Devices (2) Glaucoma And Myopia (3) Advances and Unmet Needs in Glaucoma Management (4) Glaucomatous Visual Field Abnormalities in Young Myopes. Boston. July 8-11, 2009.

Invited Speaker, Stanford University Vision Research Symposium. Glaucomatous Optic Neuropathy: Overview and Unmet Needs. Stanford, CA. May 15, 2009.

Visiting Professor, University of Wisconsin School of Medicine. (1) Landmark Clinical Trials in Glaucoma: What We Have and Have Not Learned. (2) Antifibrotic Use With Primary Trabeculectomy. Madison, WI. April 3, 2009.

Invited Speaker, Johns Hopkins University School of Medicine Current Concepts in Ophthalmology. (1) Pearls and Pitfalls of Glaucoma Filtration Surgery. (2) Should Laser Trabeculoplasty Be Initial Glaucoma Therapy. (3) Target IOP in Glaucoma Practice. Vail, CO. March 18, 2009.

Invited Speaker, Ocular Drug and Surgical Therapy Update. The Great Debate: Selective Laser Trabeculoplasty versus Medication as First Line Therapy for Glaucoma. Laguna Niguel, CA. February 14, 2009.

Invited Speaker, Glaucoma Research and Education Meeting. Normal Tension Glaucoma: Is It a Different Disease? San Francisco, CA. February 8, 2009.

Invited Speaker, SPEI Photonics Conference. Should Laser Trabeculoplasty Be Initial Therapy for Glaucoma. San Jose, CA. January 25, 2009.

Invited Speaker, The Royal Hawaiian Eye Meeting. What’s Up With IOP at Night? Implications for Diagnosis and Treatment. Wailea, HI. January 21, 2009.

Invited Speaker, Bascom Palmer Eye Institute, University of Miami School of Medicine Glaucoma Mid-Winter Symposium. Early Aggressive IOP Lowering, Target IOP and a Novel Concept for Glaucoma Care. Miami, FL. January 10, 2009.

Invited Keynote Speaker, Ophthalmology Society of Chile. International Glaucoma Lecture: Can Glaucoma Progression Be Halted By IOP Lowering. Other invited lectures: (1) Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. (2) The IOP-Glaucoma Relationship: Myth vs Reality. (3) Target IOP in Glaucoma Practice. (4) Pearls and Pitfalls of Glaucoma Filtration Surgery (5) Should Laser Trabeculoplasty Be Initial Glaucoma Therapy? (6) What To Do Next After The First Trabeculectomy Fails. December 10-13, 2008.

(12)

Page 12 of 48

Visiting Professor, University of Colorado. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. Denver, CO. November 21, 2008.

Visiting Professor, Yale University. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. New Haven, CT. November 7, 2008.

Invited Speaker, University of Toronto International Glaucoma Risk and Disease Management Symposium. Is the Patient Getting Worse? Toronto, Canada. October 18, 2008.

Visiting Professor, University of Minnesota. Randomized Clinical Trials in Glaucoma: What We Have and Have Not Learned. Minneapolis, MN. September 13, 2008.

Invited Speaker, Minnesota Academy of Ophthalmology. Can Glaucoma Progression Be Halted With IOP Lowering? September 12, 2008.

Invited Speaker, World Ophthalmology Congress 2008. (1) Collaborative Normal-tension Glaucoma Study (CNTGS) (2) Blebitis – Endophthalmitis (3) Can Glaucoma Progression Be Completely Halted by IOP Lowering? (4) Glaucomatous Optic Nerve Damage in Young Chinese Myopes (5) Laser or Medications: Who is on First? (6) Bleb and Tube Related Infections and Endophthalmitis. Hong Kong. June 28-July 2, 2008.

Invited Speaker, 31stAnnual Midwest Glaucoma Symposium. (1) Preventing Complications in Trabeculectomy Surgery. (2) Target IOP’s: Percentage Drop Versus Set Level. Omaha, Nebraska. May 16-17, 2008.

Invited Speaker, National Eye Institute. Which IOP Parameters Are Appropriate Endpoints For Glaucoma Clinical Trials? Bethesda, MD. March 13, 2008.

Invited Speaker, American Glaucoma Society Meeting. Has The Tube Versus

Trabeculectomy Study Changed My Approach in Eyes With Pseudophakia or Failed Filter? Washington D.C. March 7, 2008.

Invited Speaker, Ocular Drug and Surgical Therapy Update. Why We Need Neuroprotection. Laguna Niguel, CA. February 16, 2008.

Invited Speaker, Glaucoma Research and Education Meeting. Can Glaucoma Progression Be Stopped With IOP Lowering. San Francisco, CA. February 9, 2008.

Invited Speaker, 10th Philippine National Glaucoma Society (1) Antifibrotic Use With Primary Trabeculectomy (2) Landmark Clinical Trials in Glaucoma: What They Did and Didn’t Teach Us (3) Target IOP: Is It Necessary For Glaucoma Practice? Taped

Presentations. Manila, Philippines. February 8, 2008.

Invited Speaker. Hawaii 2008, The Royal Hawaiian Eye Meeting, CME Symposium. Goals for Glaucoma Therapy: Past, Present and Future. Waikaloa, HI. January 20, 2008.

(13)

Page 13 of 48

Invited Speaker; Stanford University Grand Rounds. Randomized Clinical Trials: Beware of Limitations. Stanford, CA. October 2, 2007.

Invited Speaker, World Glaucoma Congress of the Association of International Glaucoma Societies (1) Design Conduct and Interpretation of Clinical Trials: Pearls and Pitfalls. (2) Do Western Trials Have an Impact on Eastern Glaucoma Care? (3) The Additional Effect of Adjunctive Treatment (4) Glaucomatous Visual Field Abnormalities in Young Myopes. (4) Medical vs Laser Treatment for Glaucoma (5) Advanced Trabeculectomy Technique Video. Singapore. July 18-21, 2007.

Invited Speaker, Kaiser California Annual Ophthalmic Symposium. (1) The Major Glaucoma Trials: A Critical Analysis of the Findings. (2) Baseline Optic Nerve Head Stereophotographs Remain the Standard of Care. Anaheim, CA. June 2, 2007. Invited Speaker, Tri State (Arizona, Nevada, New Mexico) Annual Ophthalmological Meeting. Landmark Clinical Trials in Glaucoma. Las Vegas, NV. May 20, 2007. Invited Speaker, 62nd Oregon Ophthalmological Alumni Association Meeting. (1)

Landmark Glaucoma Trials: Beware of Limitations. (2) Is Setting a Target IOP Necessary in Glaucoma Practice. Portland, OR. May 18, 2007.

Invited Speaker, Fourth Global AIGS Consensus Meeting. Target Intraocular Pressure. Ft. Lauderdale, FL. May 5, 2007.

Invited Speaker, 24th Annual Wake Forest University Eye Center Conference: Glaucoma 2007. (1) Landmark Clinical Trials in Glaucoma: What They Did and Did Not Teach Us. (2) Maximal Medical Therapy for Glaucoma: When is Enough Enough? Winston-Salem, NC. April 20, 2007.

Invited Speaker, Unite For Sight 4th Annual International Health Conference. Does

Screening for Glaucoma Make Sense in the Developing World? Palo Alto, CA. April 14th, 2007.

Invited Speaker, American Glaucoma Society Meeting. Should Laser Trabeculoplasty Be First Line Therapy for Exfoliative Glaucoma? San Francisco, CA. March 2, 2007. Invited Speaker, Ocular Drug and Surgery Update. Selective Laser Trabeculoplasty vs Argon Laser Trabeculoplasty. Laguna Niguel, CA. February 17, 2007.

Invited Speaker, ALTA Ophthalmology Society. Is Target IOP Necessary for Glaucoma Practice? Sacramento, CA. February 15, 2007.

Invited Speaker, Glaucoma Research and Education Meeting. Ethnic Considerations in Glaucoma Diagnosis. San Francisco, CA. February 10, 2006.

Invited Speaker, Bascom Palmer Eye Institute, University of Miami School of Medicine Annual Glaucoma Course. Is it Necessary to Write the Target IOP in the Chart? Miami, FL. January 26-27, 2007.

(14)

Page 14 of 48

Invited Speaker, New York Glaucoma Society. The Impact of National Clinical Trials on Glaucoma Practice. New York, NY. December 7, 2006.

Invited Speaker, Southeast Asia Interest Group. (1) The Use of Antimetabolites Versus Non Antimetabolites (2) Patient Management Beyond Randomized, Controlled Trials: Early Glaucoma. Chennai, India. December 1-3, 2006.

Invited Speaker, Nebraska Academy of Ophthalmology, Annual Meeting. (1) The Impact of National Clinical Trials on Glaucoma Practice (2) Antifibrotic Use With Primary Trabeculectomy. Omaha, Nebraska. October 13-14, 2006.

Visiting Professor, University of Texas Southwestern. The Impact of National Clinical Trials on Glaucoma Practice. Dallas, Texas. September 22, 2006.

Invited Speaker, Dallas Academy of Ophthalmology. Target IOP: Is It Necessary? Dallas Texas. September 21, 2006.

Invited Speaker, Argentina Glaucoma Society Annual Meeting (1) Randomized Clinical Trials: Beware of Limitations (2) Epidemiology of Open Angle Glaucoma: Recent Developments (3) Pearls and Pitfalls of Trabeculectomy. Buenos Aires, Argentina. September 6-8, 2006.

Invited Speaker. Glaucoma Mini-Fellowship. (1) The Impact of National Clinical Trials on Glaucoma Practice (2) Improving Adherence/Compliance With Glaucoma Therapy (3) Selecting a Second Agent (4) Glaucoma and the Retina. Sonoma, CA. August 11-12, 2006.

Visiting Professor. University of Florida. (1) Target IOP: Is It Necessary for Glaucoma Practice? (2) Epidemiology of Open Angle Glaucoma: Recent Developments (3) Is Early Diagnosis of Glaucoma Important? (4) Pearls and Pitfalls of Trabeculectomy Surgery (5) Antifibrotic Use With Primary Trabeculectomy. Gainesville, FL. May 4-5, 2006. Invited Speaker. American Society of Cataract and Refractive Surgery (1) Glaucoma Day. Glaucoma Risk Assessment, Are We Making Progress? (2) Challenge Cup: Terminating Intraoperative Floppy Iris Syndrome Complications (First Prize). San Francisco, CA. March 17-21, 2006.

Invited Speaker. American Glaucoma Society Annual Meeting. Surgical Video

Symposium: Limbus Based Trabeculectomy, Antifibrotic Application and Conjunctival Closure. Charleston, SC. March 2-4, 2006.

Invited Speaker. World Ophthalmology Congress. Chair, American Academy of Ophthalmology Sponsored Symposium: Landmark Clinical Trials in Glaucoma: How They Have Impacted Practice. Sao Paulo, Brazil. February 21, 2006.

Invited Speaker. Glaucoma Research and Education Meeting. New Perspectives on Target Intraocular Pressure. San Francisco, CA. February 11, 2006.

(15)

Page 15 of 48

Invited Speaker. Hawaii 2006, The Royal Hawaiian Eye Meeting. New Perspectives on the Relationship Between IOP and Open Angle Glaucoma. Wailea, HI. January 18, 2006. Invited Speaker. University of California, San Francisco. Ophthalmology 2006: New Directions in Ocular Therapies. Ocular Hypertension and Early Glaucoma Treatment Trials. San Francisco, CA. December 1-2, 2005.

Invited Speaker, Manhattan Eye, Ear and Throat Hospital. Greater New York Clinical Ophthalmology Series (1) The Impact of National Clinical Trials on Glaucoma Practice (2) Antifibrotic Use With Primary Trabeculectomy. New York, NY. November 16, 2005. Invited Speaker, Columbia University College of Physicians and Surgeons. New Frontiers in Clinical Glaucoma. (1) Epidemiology of Glaucoma (2) Clinical Pearls in Filtering Surgery. New York, NY. November 11-12th, 2005.

Visiting Professor, University of Oklahoma, Dean McGee Eye Institute. (1) How to Evaluate the Quality of Randomized Clinical Trials in Glaucoma (2) Antifibrotic Use With Primary Trabeculectomy. Oklahoma City, OK. October 3, 2005.

Invited Speaker. Association of International Glaucoma Societies. Inagural Meeting. (1) What Did We Learn From the European Glaucoma Prevention Study? (2) Comparison of Glaucoma Drainage Devices and Cyclodestructive Procedures (3) Chair, Design, Conduct and Interpretation of Randomized Clinical Trials: Pearls and Pitfalls. Vienna, Austria. July 6-9th, 2005.

Invited Speaker. Midwest Glaucoma Symposium. (1) Landmark Clinical Trials in

Glaucoma AGIS, EMGT and CNTGS: What Have We Learned? (2) Antifibrotic Use With Primary Trabeculectomy. Cincinnati, OH. May 21, 2005.

Invited Speaker. Innovations in Glaucoma: What’s New, What’s Really True? CME Regional Meeting. (1) Contemporary Insights on Corneal Thickness (2) Argon Laser Trabeculoplasty vs Selective Laser Trabeculoplasty. Newport Beach, CA. May 14, 2005. Invited Speaker and Panel Chair. 2nd Global Association of International Glaucoma

Societies Consensus Meeting: Glaucoma Surgery, Open Angle Glaucoma.

Cyclodestruction versus Glaucoma Drainage Devices. Ft. Lauderdale, FL. April 30, 2005. Visiting Professor. University of Missouri. Antifibrotic Use With Primary

Trabeculectomy. Kansas City, MO. April 20, 2005.

Visiting Professor. Massachusetts Eye and Ear Infirmary, Harvard Medical School. Antifibrotic Use With Primary Trabeculectomy. Boston, MA. April 18-19, 2005. Invited Speaker. Glaucoma Day, American Society of Cataract and Refractive Surgery Annual Meeting. (1) Does Early Diagnosis Matter? (2) Maximal Medical Therapy: How Many Bottles Does it Take? (3) Should Laser Trabeculoplasty Be Initial Therapy For Glaucoma Secondary to Exfoliation Syndrome? Washington D.C. April 15, 2005.

(16)

Page 16 of 48

Invited Speaker. New Orleans Academy of Ophthalmology, 54th Annual Symposium (1) The Impact of National Clinical Trials on Glaucoma Practice (2) Principles of Blebitis Therapy (3) What Constitutes Clinical Effectiveness of Glaucoma Therapy (4) Maximal Medical Therapy: When is Enough Enough? (5) Pearls and Pitfalls of Filtration Surgery (6) Target IOP in Glaucoma Therapy. New Orleans, LA. February 18-20, 2005.

Invited Speaker. Glaucoma Research and Education Meeting. Antifibrotic Use With Primary Trabeculectomy. San Francisco, CA. February 5, 2005.

Invited Speaker. Colorado Society of Eye Physicians and Surgeons, 90th Annual Meeting. (1) Antifibrotic Use With Primary Trabeculectomy (2) Pearls and Pitfalls of Glaucoma Filtration Surgery (3) Landmark Clinical Trials in Glaucoma: What We Have Learned (4) Maximal Medical Therapy: When is Enough Enough? Breckenridge, CO. January 28-30, 2005.

Invited Speaker. Hawaii 2005, The Royal Hawaiian Eye Meeting. Risk Assessment in the Glaucoma Continuum. Kona, HI. January 19, 2005.

Visiting Professor. Duke University Dinner Series: Antifibrotic Use With Primary Trabeculectomy. Durham, NC. November 15, 2004.

Stanford University School of Medicine Symposium. Bias and Conflict of Interest in Clinical Trials: Real and Perceived. Stanford, CA. November 9, 2004.

Visiting Lecturer. San Diego Naval Hospital. The Impact of National Clinical Trials on Glaucoma Practice. San Diego, CA. October 14, 2004.

Invited Speaker. Tri-County Eye Society. The Impact of National Clinical Trials on Glaucoma Practice. Riverside, CA. October 13, 2004.

Visiting Professor. Moran Eye Center, University of Utah. The Impact of National Clinical Trials on Glaucoma Practice. Salt Lake City, UT. June 15, 2004.

European Glaucoma Society Meeting. Randomized Clinical Trial of Trabeculectomy with Intraoperative Mitomycin C versus 5-Fluorouracil: Intermediate Term Results. Florence, Italy. June 3, 2004.

Visiting Professor. Doheny Eye Institute, University of Southern California. The Impact of National Clinical Trials on Glaucoma Practice. Los Angeles, CA. April 10, 2004. American Glaucoma Society Annual Meeting. Randomized Clinical Trial of

Trabeculectomy with Intraoperative Mitomycin C versus 5-Fluorouracil: Intermediate Term Results. Sarasota, FL. March 6, 2004.

Invited Speaker. CORE Resident and Fellow Educational Program. Western Region. Recent Glaucoma Clinical Trials. San Francisco, CA. February 27-28, 2004.

(17)

Page 17 of 48

Invited Speaker. Ocular Drug and Surgery Update. Update on Blebitis. Laguna Niguel, CA. February 15, 2004.

Invited Speaker. Glaucoma Research and Education Meeting. Risk Assessment in Glaucoma Patients: Utilizing Results from National Clinical Trials. San Francisco, CA. February 7, 2004.

Invited Speaker. Hawaii 2004, The Royal Hawaiian Eye Meeting. Update on Antifibrotic Use Adjunctive to Glaucoma Surgery. Kuaui, Hawaii. January 28, 2004. Awarded Most Outstanding Speaker on Glaucoma Day.

Visiting Professor. Oregon Health Sciences University. (1) Epidemiology and Classification of the Glaucomas. (2) Recent Clinical Trials and the Rationale for IOP Lowering. Portland, OR. November 21, 2003.

Invited Speaker. Bridgeport Glaucoma Society. Antifibrotic Choice With Primary Trabeculectomy. Portland, OR. November 20, 2003.

Invited Speaker at Glaucoma Symposium of the American Academy of Ophthalmology. IOP, Tonometry and Corneal Thickness. Anaheim, CA. November 17, 2003.

Invited Panelist, Association of International Glaucoma Societies Consensus Meeting. Sensitivity and Specificity of Stuctural and Functional Tests in Glaucoma. San Diego, CA. November 13, 2003.

Visiting Professor. Royal Victoria Eye and Ear Hospital, Risk Assessment in Patients with Ocular Hypertension and Glaucoma. Melbourne, Australia. October 16, 2003.

Invited Speaker. Glaucoma 2003: Contemporary Issues in Glaucoma Diagnosis and Therapy (1) Are All Prostaglandins Alike? (2) Risk Management in Glaucoma. Chicago, IL. June 13, 2003.

Invited Speaker. Medical College of Virginia. Antifibrotic Use With Primary Trabeculectomy Richmond, VA. June 2, 2003.

Invited Speaker. Miami Ophthalmology Society. Evidence Based Approach to Ocular Hypertensive and Glaucoma Patients. Miami, FL. May 8, 2003.

Visiting Grand Rounds Professor. Emory University. Antifibrotic Use With Primary Trabeculectomy Atlanta, GA. May 2, 2003.

Invited Speaker. American Society of Cataract and Refractive Surgery. (1) Glaucoma Surgery: Pearls and Pitfalls. (2) Decoding the Alphabet Soup of Recent Glaucoma

Studies: The Ocular Hypertension Treatment Study. (3) Chair, Paradigm Shift in the Initial Medical Management of Glaucoma and Ocular Hypertension. (4) First Line Medical Therapy for Ocular Hypertension and Glaucoma. San Francisco, CA. April 12-13, 2002.

(18)

Page 18 of 48

Invited Speaker. American Glaucoma Society Meeting. Conjunctival Flap Closure Pearls. San Francisco, CA. March 8, 2003.

Invited Speaker. Annual Glaucoma Research and Education Group Meeting. Glaucoma Surgery: Pearls and Pitfalls. San Francisco, CA. February 8, 2003.

Visiting Professor, California Pacific Medical Center. What Does Ocular Hypertension Mean to the Clinician? San Francisco, CA. February 3. 2003.

Invited Speaker, Royal Hawaiian Eye Meeting. What Does Ocular Hypertension Mean to the Clinician? Maui, Hawaii. January 19, 2003.

Visiting Professor, University of California at San Francisco. Maximal Medical Therapy for Glaucoma: Know When to Say When. San Francisco, CA. October 10, 2002. Invited Speaker. 100th Anniversary Meeting of the Deutsche Ophthalmologische Gessellschaft (German Ophthalmology Society.) Maximal Medical Therapy for Glaucoma: When is Enough Enough? Berlin, Germany. September 28, 2002.

Visiting Professor. New York University and Manhattan Eye, Ear and Throat Hospital. 1) Antimetabolite Use With Primary Trabeculectomy. 2) Medical Therapy for Glaucoma: Balancing Safety, Efficacy and Tolerability. New York, NY. September 24, 2002. Invited Speaker. Chicago Ophthalmological Society. Glaucoma Therapy: Balancing Safety, Efficacy and Tolerability. Chicago, IL. September 23, 2002.

Invited Speaker. Michigan Ophthalmology Society Annual Meeting. 1) Target IOP in Glaucoma Therapy 2) Maximal Medical Therapy for Glaucoma: Know When to Say When 3) Antimetabolite Use With Primary Trabeculectomy. Mackinac Island, MI. August 9-10th, 2002.

Invited Speaker. The Pacific Coast Oto-Ophthalmological Society 85th Annual Meeting IOP and Glaucoma: Setting the Target. Lake Tahoe, NV. June 22, 2002.

Invited Speaker. International Congress of Ophthalmology. 1) Trabeculectomy and Antifibrosis Agents; 2) 24-Hour IOP Control: Is it Needed?; 3) Medical Therapy for Glaucoma: Balancing Efficacy, Safety, and Tolerability. Sydney, Australia. April 20-24, 2002.

Invited Speaker. Ophthalmology Society of South Africa Annual Meeting. 1) Perspectives on the Relationship Between IOP and Glaucoma: What We Have Learned from

Epidemiologic Studies. 2) Paradigm Shifts in the Medical Management of Glaucoma. 3) Antimetabolite Use with Primary Trabeculectomy. 4) Antimetabolite Use with Combined Cataract and Glaucoma Surgery. Durban, South Africa. March 2-5, 2002.

Invited Speaker. Bascom Palmer Eye Institute, University of Miami 40th Anniversary Meeting. Advances in Aqueous Outflow Pharmacology. Coral Gables, FL. February 21, 2002.

(19)

Page 19 of 48

Invited Speaker. Ocular Drug and Surgery Update. Target Intraocular Pressure: How to Select It. Dana Point, CA. February 16, 2002.

Invited Speaker. Swiss Ophthalmology Society Winter Symposium. Strategies in the Medical Treatment of Glaucoma (Telepresentation). Villars, Switzerland. January 25, 2002.

Invited Speaker. New Jersey Academy of Ophthalmology. (1) Perspectives on the

Relationship Between IOP and Glaucoma; (2) Surgery, Is Newer Truly Better? Eatontown, NJ. October 10, 2001.

Invited Speaker, Northern Virginia Society of Ophthalmology . Clinical Decisions Based on the Relationship Between Intraocular Pressure and Glaucomatous Optic Neuropathy, Fairfax, Virginia. May 21, 2001.

Invited Speaker, Las Vegas Ophthalmology Society. Paradigm Shifts in the Medical Management of Glaucoma. Las Vegas, NV. May 16, 2001.

Invited Speaker, Palm Beach Ophthalmology Society. Clinical Decisions Based on the Relationship Between Intraocular Pressure and Glaucomatous Optic Neuropathy. Palm Beach, FL. April 30, 2001.

Invited Speaker, San Diego Ophthalmology Society. Clinical Decisions Based on the Relationship Between Intraocular Pressure and Glaucomatous Optic Neuropathy. San Diego, CA. April 16, 2001.

Visiting Professor. University of California San Diego: Mitomycin C versus 5-FU with Primary Trabeculectomy. San Diego, CA. April 16, 2001.

Invited Speaker, International Glaucoma Society Meeting. Clinical Decisions Based on the Relationship Between Intraocular Pressure and Glaucomatous Optic Neuropathy. Prague, Czech Republic. March 24, 2001.

Invited Keynote Speaker. Symposium on Mitomycin C. 18th Congress of the Asia-Pacific Academy of Ophthalmology: Intraoperative Mitomycin C and 5-Fluorouracil Use with Primary Trabeculectomy. Taipei, Taiwan. March 10-14, 2001.

Visiting Lecturer, Ludwig Maxmillian University. Paradigm Shifts in the Medical Management of Glaucoma. Munich, Germany. November 27, 2000.

Invited Speaker, Japanese Ophthalmology Society Annual Meeting. Paradigm Shifts in the Medical Management of Glaucoma. Tokyo, Japan. November 4, 2000.

Visiting Professor, University of Toronto. (1) The Use of Antimetabolite Drugs with Primary Trabeculectomy; (2) Secondary Open Angle Glaucoma. Toronto, Canada. October 12-13, 2000.

(20)

Page 20 of 48

Visiting Professor, Malmo University. Paradigm Shifts in the Medical Management of Glaucoma, Malmo, Sweden. September 28, 2000

Visiting Professor, Molndals Eye Clinic, Sahlgrenska Institute, University of Gothenburg. Paradigm Shifts in the Medical Management of Glaucoma, Gothenburg, Sweden.

September 27, 2000.

Visiting Professor, St. Eriks Eye Hospital, Karolinska Institute, Stockholm University. Paradigm Shifts in the Medical Management of Glaucoma, Stockholm, Sweden. September 26, 2000.

Invited Speaker, California Academy of Ophthalmology. The Use of Antifibrotic Agents with Combined Cataract and Glaucoma Surgery, San Francisco, CA. September 16, 2000. Invited Speaker, Mexican Congress of Ophthalmology. Paradigm Shift in Medical Therapy for Glaucoma. Monterrey, Mexico. July 30, 2000.

Primary Trabeculectomy with Intraoperative Mitomycin C (MMC) versus 5-Fluorouracil (5-FU): Intermediate Term Results. 6th Congress of the European Glaucoma Society, London, U.K., June 26-29, 2000.

Invited Speaker, ALTA Ophthalmology Society. Paradigm Shifts in the Medical Management of Glaucoma Sacramento, CA. February 15, 2000.

Visiting Professor, Medical College of Georgia. Medical Therapy for Glaucoma with the Emergence of New Agents. The Use of Antifibrotic Agents with Trabeculectomy and Combined Cataract and Glaucoma Surgery. Augusta, GA. January 15, 2000.

Surgical Frontiers for Y2K. Update on Antifibrotic Agents in Glaucoma Surgery. University of California at San Francisco. San Francisco, CA. December 2, 1999. 103rd American Academy of Ophthalmology Annual Meeting (Joint Meeting with Pan American Association of Ophthalmology). Trabeculectomy with Intraoperative

Mitomycin C (MMC) versus 5-Fluorouracil (5-FU): Randomized Clinical Trial. Presented at AAO Meeting, Orlando, Florida. October 26, 1999.

Invited Speaker, Chicago Ophthalmology Society: (1) The Use of Antifibrotic Drugs with Combined Cataract and Glaucoma Surgery. (2) Medical Therapy for Glaucoma with the Emergence of New Agents. Chicago, IL. October 18, 1999.

Department of Ophthalmology, Stanford University. Doctor I Know I Have Glaucoma But I Want to Drive. Stanford, CA. October 2, 1999.

Invited Speaker, Idaho Ophthalmology Society. (1)Recent Advances in the Medical Management of Glaucoma. (2)The Use of Antifibrotic Drugs with Combined Cataract and Glaucoma Surgery. Sun Valley, ID. August 20-21, 1999.

(21)

Page 21 of 48

Visiting Professor, Moorfields Eye Hospital and the Institute for Ophthalmology. The Use of Antifibrotic Drugs with Primary Trabeculectomy. London, U.K., June 23, 1999.

Invited Speaker, Santa Barbara Ophthalmology Society. Medical Therapy for the

Treatment of Glaucoma with the Introduction of New Agents. Santa Barbara, CA. June 17, 1999.

Visiting Professor, University of Arizona. Primary and Secondary Open Angle Glaucomas. Tucson, AZ. May 21, 1999.

Invited Speaker, Tucson Ophthalmology Society: Medical Therapy for the Treatment of Glaucoma with the Introduction of New Agents. Tucson, AZ. May 20, 1999.

Invited Speaker, Kaiser Ophthalmology of Northern California. Antimetabolite Use with Seton Implantation. San Francisco, CA. January 21, 1999.

Invited Speaker, Medford Ophthalmology Society. Medical Therapy for the Treatment of Glaucoma with the Introduction of New Agents. Medford, OR. December 14, 1998. Invited Speaker, Spokane Ophthalmology Society. Recent Advances in the Medical Therapy for Glaucoma. Spokane, WA. December 9, 1998.

Invited Speaker, Oregon Ophthalmological Society. Antimetabolite Use with Combined Cataract and Glaucoma Surgery. Portland, OR. September 18, 1998.

Invited Speaker, Winnipeg Ophthalmology Society. Medical Therapy of Glaucoma with the Introduction of New Agents. Winnipeg, Canada. September 11, 1998.

Invited Speaker, Dayton Ophthalmology Society. Update on Glaucoma Medical Therapy and Hypotony Maculopathy. Dayton, Ohio. June 2, 1998.

Invited Speaker, Santa Barbara Ophthalmology Society. Antimetabolite Use with Glaucoma Surgery. Santa Barbara, CA. May 28, 1998.

Invited Speaker, Kaiser Ophthalmology Continuing Education Course - Excellence in Cataract Surgery. The Use of Antimetabolite Agents in Combined Cataract and Glaucoma Procedures. Update on Hypotony Maculopathy. Oakland, CA. May 9, 1998.

Invited Speaker, Barkan Symposium and Scientific Day, California Pacific Medical Center Annual Meeting. New Glaucoma Therapy and Selective Laser Trabeculoplasty.

Monterey, CA. May 8, 1998.

Invited Speaker, British Columbia Ophthalmology Society Annual Meeting.

Antimetabolite Choice with Primary Trabeculectomy. Vancouver, Canada. May 1998. Invited Speaker, Hawaiian Ophthalmology Society. Medical Therapy for Glaucoma with the Emergence of New Agents. Honolulu, HI. March 26, 1998.

(22)

Page 22 of 48

Invited Speaker, Ophthalmology Society of the Redwoods. Medical Therapy for Glaucoma with the Emergence of New Agents. Santa Rosa, CA. March 9, 1998. Visiting Professor, University of Chicago. Antimetabolite Choice with Primary Trabeculectomy. Chicago, IL. February 22, 1998.

Visiting Professor, University of California Berkeley, College of Optometry. Primary Open Angle Glaucoma Today. Berkeley, CA. December 8, 1997.

Invited Speaker, The San Diego Eye Bank . Medical and Surgical Therapy of Glaucoma Update. San Diego, CA. November 20, 1997.

Visiting Professor. Loma Linda University. Antimetabolite Choice with Primary Trabeculectomy. Loma Linda, CA. November 7, 1997.

Visiting Professor. Moorfields Eye Hospital and the Institute for Ophthalmology. Antimetabolite Choice with Primary Trabeculectomy, London, U.K., October 31, 1997. Invited Speaker, California Pacific Medical Center, Perspectives in Medical Therapy for Glaucoma. San Francisco, CA. October 26, 1997.

Visiting Professor, University of California at San Francisco. Antimetabolite Choice with Primary Trabeculectomy. San Francisco, CA. October 9, 1997.

Invited Speaker, Kanawha Ophthalmology Society. Recent Advances in the Medical and Surgical Management of Glaucoma, Charleston, West Virginia. September 23, 1997. Visiting Professor. University of Pittsburgh, Recent Advances in the Medical and Surgical Management of Glaucoma. Pittsburgh, PA. September 22, 1997.

Invited Speaker, South Colorado Ophthalmology Society, Recent Advances in Medical and Surgical Management of Glaucoma. Colorado Springs, CO. June 11, 1997.

Invited Speaker, Scripps Clinic and Research Foundation. Pearls of Ocular Therapy (1) Current Medical Therapy of Glaucoma. (2) Antimetabolite Choice with Primary

Trabeculectomy, La Jolla, CA. May 3, 1997.

Invited Speaker, Savannah Ophthalmology Society. Recent Advances in the Medical and Surgical Management of Glaucoma. Savannah, GA. March 27, 1997.

Visiting Professor. Eastern Virginia Medical College. Trabeculectomy for the General Ophthalmologist, Norfolk, Virginia. March 12, 1997.

Invited Grand Rounds Speaker, Santa Rosa Memorial Hospital. Common Causes of Vision Loss. Santa Rosa, CA. February 7, 1997.

Invited Speaker, Tucson Ophthalmology Society. 5-FU vs Mitomycin C in Primary Trabeculectomy. October 10, 1996.

(23)

Page 23 of 48

Visiting Professor, University of Arizona, Secondary Open Angle Glaucomas. Tucson, AZ, October 10-11, 1996.

5-FU vs Mitomycin C in Primary Trabeculectomy. Stanford University Department of Ophthalmology Alumni Meeting, Stanford, CA. September 27, 1996.

Invited Speaker, University of Colorado Health Sciences Center. Antimetabolites and Glaucoma Filtration Surgery, Denver, CO. August 28, 1996.

Visiting Professor, University of New Mexico, What's New in Glaucoma Therapy? Albuquerque, NM. June 13, 1996.

Invited Speaker, Pierce County Ophthalmology Society Meeting. What's New in Glaucoma Therapy? Tacoma, Washington. March 29, 1996.

Visiting Professor, University of Washington. Antifibrotic Agents in Glaucoma Therapy. Seattle, WA. March 29, 1996

Invited Speaker, Meredith Morgan Symposium, University of California, Berkeley. , Berkeley, CA. March 26, 1996.

Visiting Professor. University of Texas at San Antonio. Antifibrotic Agents in Glaucoma Therapy. San Antonio, TX. February 16, 1996.

Invited Speaker, San Antonio Ophthalmology Society. What's New in Glaucoma Therapy? San Antonio, TX. February 15, 1996.

Antimetabolites and Glaucoma Filtration Surgery. Salem Hospital Continuing Medical Education. Salem, OR. October 5, 1995.

Invited Speaker, Chicago Glaucoma Society. The Role of Antimetabolites Adjunctive to Primary Trabeculectomy. Chicago, IL. September 21, 1995.

Glaucoma Surgery Update. Modern Anterior Segment Surgery/Alumni Meeting. Stanford, CA. September 15, 1995.

Invited Speaker, New Perspectives in Glaucoma; Hypotony: Causes, Consequences, and Therapy. Devers Eye Institute Portland, OR. June 10, 1995.

Visiting Professor, Glaucoma Surgery Update. Flinders University Medical Center, Adelaide, Australia. May 9, 1995.

Visiting Professor. Antimetabolites and Glaucoma Filtration Surgery. Royal Victoria Eye and Ear Hospital, Melbourne, Australia. May 4-5, 1995.

Invited Speaker, Twilight Glaucoma Meeting, Antimetabolites and Glaucoma Filtration Surgery. Sydney, Australia. May 3, 1995.

(24)

Page 24 of 48

Visiting Professor. Jules Stein Eye Institute, UCLA. Antimetabolites and Glaucoma Filtration Surgery. February 1994.

Visiting Professor, Rajendra Prasad Center for Ophthalmic Sciences (RPC) - All India Institute for Medical Sciences, New Delhi, India. December 1993.

Visiting Lecturer, Glaucoma Surgery Update. Aravind Eye Hospital, Madurai, India. December 1993.

Invited Speaker, Glaucoma Surgery Update. All India Glaucoma Congress, Madras, India. November 1993.

Antimetabolites and Glaucoma Filtration Surgery, Pacific Coast Ophthalmology Society, Portland, OR. September 1993.

Antimetabolites and Glaucoma Filtration Surgery. Bridgeport Glaucoma Society. Portland, Oregon. August 1992.

Visiting Lecturer, University of Pittsburgh. Recent advances in Glaucoma Filtration Surgery. November 1991.

Acute Idiopathic Blind Spot Enlargement: A Spectrum of Disease. Paper presentation at the American Academy of Ophthalmology (AAO) annual meeting, Atlanta. October 1990. Photographic Simulation of the Dimunition of Vision. Presented at the Wilmer Resident's Association Meetings. April 1986.

A New Recombinant DNA Hepatitis Vaccine. Presented at the National Institute of Health Fellowship Meetings. July 1983.

Lectures at Bay Area Basic Science Course at Stanford

• Section Chief, Glaucoma. 2006-2013.

• Landmark Clinical Trials in Glaucoma. 2006-2013.

• Epidemiology of Glaucoma. 2006-2013.

• Epidemiology and International Aspect of the Glaucomas. 1997-1998.

• Epidemiology and Biostatistics (Section Chief). 1993-2003.

• Glaucoma Pharmacology. 2003.

• Secondary Open-Angle Glaucoma. 1993-2003.

• Primary Open-Angle Glaucoma. 1993-2003.

• Aqueous Humor Dynamics. 1993-1996.

(25)

Page 25 of 48

Other Annual Lectures

• Moderator, glaucoma sessions at the annual Association for Research in Vision and Ophthalmology meeting, Ft Lauderdale, FL: 2000-2011, Seattle, WA: 2013.

• Glaucoma Resident Lectures. University of California, San Francisco. 1993- 1999, 2002-2008.

American Academy of Ophthalmology: Invited Lectures and Courses

2012 Glaucoma Subspecialty Day. Chicago, IL. (1) Program Committee Chair,

Moderator and Panel Chair, Progression at Normal Pressures. November 10, 2012. (2) Academy Café: Glaucoma

2011 Glaucoma Subspecialty Day. Orlando, FL. (1) Program Committee Chair and Moderator, Challenging Glaucoma Section. October 22, 2011. (2) Academy Café: Glaucoma.

2010 Glaucoma Subspecialty Day. San Francisco, CA. (1) Introduction of the American Glaucoma Society Glaucoma Subspecialty Day Keynote Lecturer Alfred Sommer. (2) Do We Need to Diagnose and Treat Pre-Perimetric Glaucoma? No. October 16, 2010. (3) Academy Café: Glaucoma.

2009 Glaucoma Subspecialty Day. San Francisco, CA. (1) Cataract Surgery is Not the Best Procedure in a Patient With Cataract and Uncontrolled Glaucoma. October, 2009. (2) Academy Café: Glaucoma.

2008 Glaucoma Subspecialty Day. Atlanta, GA. How My Approach Differs for Normal Tension Glaucoma. November 8, 2008.

2007 Program Committee, Glaucoma Subspecialty Day. New Orleans, LA Glaucoma Progression Can Not Be Stopped With IOP Lowering. November 10, 2007.

2006 Program Committee, Glaucoma Subspecialty Day. Las Vegas, NV Is Selection of a Target IOP Necessary for Glaucoma Management? November 11, 2006.

2005 Program Committee, Glaucoma Subspecialty Day. Chicago, IL. Why Ocular Hypertension Treatment Study and European Glaucoma Prevention Study Results Differ. October 15, 2005. Discussant, Free Papers in Glaucoma. 2004 Program Committee, Glaucoma Subspecialty Day. New Orleans, LA Moderator, Controversies I: Medical Therapy. Discussant, Free Papers in Glaucoma.

(26)

Page 26 of 48

2002 Co-Chair, Glaucoma Subspecialty Day. Under Pressure: Vision for the Future. Orlando, FL

2001 Glaucoma Subspecialty Day, New Orleans, LA. Maximal Medical Therapy, When is Enough Enough?

2000 Glaucoma Subspecialty Day. Dallas, TX. Creation and Closure of the Limbus Based Trabeculectomy Flap. October 21, 2000.

1999 Glaucoma Subspecialty Day. Orlando, FL. Management of the Shallow Anterior Chamber. Orlando, FL, October 23, 1999.

1997 Glaucoma Subspecialty Day. San Francisco, CA Antimetabolite Use Adjunctive to Glaucoma Surgery: An Update. October 25, 1997. 1996-2010 Glaucoma Filtration Surgery - Didactic and Laboratory

1996-2011 Phacoemulsification in the Glaucoma Patient - Didactic and Laboratory 2011-2012 Glaucoma Filtration Surgery- Didactic

2011 Phacoemulsification in the Glaucoma Patient-Didactic 1995 Laser Applications in Glaucoma - Basic Laboratory 1994 Interpretation of Automated Perimetry

Original, Peer Reviewed Publications: (121)

Pasquale LR, Loomis SJ, Weinreb RN, Kang JH, Yaspan BL, Bailey JC, Gaasterland D, Gaasterland T, Lee RK, Scott WK, Lichter PR, Budenz DL, Liu Y, Realini T, Friedman DS, McCarty CA, Moroi SE, Olson L, Schuman JS, Singh K, Vollrath D, Wollstein G, Zack DJ, Brilliant M, Sit AJ, Christen WG, Fingert J, Kraft P, Zhang K, Allingham RR, Pericak-Vance MA, Richards JE, Hauser MA, Haines JL, Wiggs JL. Estrogen Pathway Polymorphisms in Relation to Primary Open Angle Glaucoma: An Analysis Accounting for Gender From the United States. Molecular Vision 19:1471-81 July 12, 2013.

Ung C, Zhang E, Alfaro T, Murakami Y, Zhang M, Seider MI, Lin SC, Singh K. Glaucoma Severity and Medication Adherence in a County Hospital Population. Ophthalmology 120(6):1150-7 Jun, 2013.

Kozner P, Simonova K, Brozek B, Singh K. Late Acute Myopia Syndrome Induced by Combination of Sulfonamide Drugs. Journal of Glaucoma May, 2013.

(27)

Page 27 of 48

Ung C, Murakami Y, Zhang E, Alfaro T, Zhang M, Seider MI, Singh K, Lin SC. The Association Between Compliance With Recommended Follow-up and Glaucomatous Disease Severity in a County Hospital Population. American Journal of Ophthalmology. April, 2013.

Panarelli JF, Banitt MR, Sidoti PA, Budenz DL, Singh K. Clinical Impact of 8 Prospective, Randomized, Multicenter Glaucoma Trials. Journal of Glaucoma. April, 2013.

Chang RT, Singh K. Myopia and Glaucoma: Diagnostic and Therapeutic challenges. Current Opinion in Ophthalmology 24(2):96-101. Mar, 2013.

Desai RU, Singh K, Lin SC. Intravitreal Ranibizumab as an Adjunct for Ahmed Valve Surgery in Open Angle Glaucoma: A Pilot Study. Clinical Experimental Ophthalmology 41(2):155-8, Mar, 2013..

Pasquale LR, Loomis SJ, Kang JH, Yaspan BL, Abdrabou W, Budenz DL, Chen TC, Delbono E, Friedman DS, Gaasterland D, Gaasterland T, Grosskreutz CL, Lee RK, Lichter PR, Liu Y, McCarty CA, Moroi SE, Olson LM, Realini T, Rhee DJ, Schuman JS, Singh K, Vollrath D, Wollstein G, Zack DJ, Allingham RR, Pericak-Vance MA, Weinreb RN, Zhang K, Hauser MA, Richards JE, Haines JL, Wiggs JL. CDKN2B-AS1

Genotype-Glaucoma Feature Correlations in Primary Open-Angle Genotype-Glaucoma Patients from the United States. American Journal of Ophthalmology 155(2):342-353. Feb, 2013.

Charalel RA, Lin HS, Singh K. Glaucoma Screening Using Relative Afferent Pupillary Defect. Journal of Glaucoma Jan, 2013.

Qiu M, Wang SY, Singh K, Lin SC. Association between Myopia and Glaucoma in the United States Population. Investigative Ophthalmology Visual Science 54(1):830-5 Jan, 2013.

Sáles CS, Lee RY, Agadzi AK, Hee MR, Singh K, Lin SC. Open Angle Glaucoma in Filipino and White Americans: A Comparative Study. Journal of Glaucoma Dec, 2012. Sáles CS, Lee RY, Agadzi AK, Hee MR, Singh K, Lin SC. Prevalence of Diabetes Mellitus and Diabetic Retinopathy in Filipino vs Caucasian Americans: a Retrospective Cross-sectional Epidemiologic Study of two convenience samples. Ethnicity and Disease 22(4):459-65. Autumn, 2012.

Chang RT, Shingleton BJ, Singh K. Timely cataract surgery for improved glaucoma management. Journal of Cataract and Refractive Surgery 38(10):1709-10. Oct, 2012. Wang SY, Singh K, Lin SC. Prevalence and Predictors of Depression among participants with Glaucoma in a nationally representative population sample. American Journal of Ophthalmology 154(3):436-444.e2. Sep, 2012.

Lerner SF, Singh K, Susanna R Jr, Wilson MR, Lee BL, Maul E; Latin America Glaucoma Rand Study Group. RAND-like Appropriateness Methodology Consensus for Primary

(28)

Page 28 of 48

Open-Angle Glaucoma in Latin America. American Journal of Ophthalmology 154(3) 460-465.e7. Sept, 2012.

Choi DY, Suramethakul P, Lindstrom RL and Singh K. Glaucoma Surgery With or Without Cataract Surgery, Revolution or Evolution. Journal of Cataract and Refractive Surgery 38(7) 1121-22. July, 2012.

Ulmer M, Li J, Yaspan BL, Ozel AB, Richards JE, Moroi SE, Hawthorne F, Budenz DL, Friedman DS, Gaasterland D, Haines J, Kang JH, Lee R, Lichter P, Liu Y, Pasquale LR, Pericak-Vance M, Realini A, Schuman JS, Singh K, Vollrath D, Weinreb R, Wollstein G, Zack DJ, Zhang K, Young T, Allingham RR, Wiggs JL, Ashley-Koch A, Hauser MA. Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the NEIGHBOR and GLAUGEN consortia.Investigative Ophthalmology Visual Science 3;53(8):4468-74. Jul, 2012.

Wiggs JL, Hauser MA, Abdrabou W, Allingham RR, Budenz DL, Delbono E, Friedman DS, Kang JH, Gaasterland D, Gaasterland T, Lee RK, Lichter PR, Loomis S, Liu Y, McCarty C, Medeiros FA, Moroi SE, Olson LM, Realini A, Richards JE, Rozsa FW, Schuman JS, Singh K, Stein JD, Vollrath D, Weinreb RN, Wollstein G, Yaspan BL, Yoneyama S, Zack D, Zhang K, Pericak-Vance M, Pasquale LR, Haines JL. The NEIGHBOR Consortium Primary Open-Angle Glaucoma Genome-wide Association Study: Rationale, Study Design, and Clinical Variables. Journal of Glaucoma Jul 23, 2012. Wang D, He M, Wu L, Kao A, Pekmezci M, Singh K, Lin S. Dark-light Change of Iris Parameters and Related Factors Among American Caucasians, American Chinese and Mainland Chinese. Current Eye Research Vol. 37(7) 599-605. July, 2012.

Kumar RS, Baskaran M, Singh K, Aung T. Clinical Characterization of Young Chinese Myopes with Optic Nerve and Visual Field Changes Resembling Glaucoma. Journal of Glaucoma 21 (5): 281-6. Jun-Jul; 2012.

Chang Ta, Budenz D, Liu A, Kim W, Dang DQ, Li C, Iwach A, Radhakrishnan S, Singh K. Long-term Effect of Phacoemulsification on Intraocular Pressure Using the Phakic Fellow Eye as a Control. Journal of Cataract and Refractive Surgery 38(5):866-70. May, 2012. Wiggs JL,Yaspan BL, Hauser MA, Kang JH, Allingham RR, Olson LM, Abdrabou W, Fang B, Wang D, Brodeur, W, Budenz DL, Caprioli J, Crenshaw A, Crooks K, DebBono E, Doheny KF, Friedman DS, Gaasterland D, Gaasterland T, Laurie C, Lee R, Lichter PR, Loomis S, Liu Y, Medeiros FA, McCarty C, Mirel D, Moroi SE, Musch DC, Realini A, Rozsa FW, Schuman JS, Scott K, Singh K, Stein JD, Trager EH, VanVeldhuisen P, Vollrath D, Wollstein G, Yoneyyama S, Zhang K, Weinreb RN, Masuda T, Zack D,

Richards JE, Pericak-Vance M, Pasquale LR and Haines JL. Common Variants at 9p21and 8q22 are associated with increased susceptibility to Optic Nerve Degeneration in

Glaucoma. PLoS Genetics 8(4):e1002654. April, 2012.

Wang SY, Singh K, Lin SC. The Association between Glaucoma Prevalence and Supplementation with the Oxidants Calcium and Iron. Investigative Ophthalmology and Visual Science 13;53(2):725-31. Feb, 2012.

(29)

Page 29 of 48

Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Tube versus Trabeculectomy Study Group. Postoperative Complications in the Tube Versus

Trabeculectomy (TVT) Study During Five Years of Follow-up. American Journal of Ophthalmology 153 (5) 804-814.el, 2012.

Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Tube versus Trabeculectomy Study Group. Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-up. American Journal of Ophthalmology 153(5) 789-803.e2, 2012.

Gedde SJ, Singh K, Schiffman JC, Feuer WJ. The Tube Versus Trabeculectomy Study: Interpretation of Results and Application to Clinical Practice. Current Opinion in Ophthalmology 23(2):118-26. Mar, 2012.

Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser Trabeculoplasty for Open-angle Glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology 118(11):2296-302. Nov, 2011.

Singh K and Sit AJ. Intraocular Pressure Variability and Glaucoma Risk: Complex and Controversial. Archives of Ophthalmology 129(8):1080-1. August, 2011.

Wang D, He M, Wu L, Yaplee S, Singh K, Lin S. Differences in Iris Structural

Measurements among American Caucasians, American Chinese and mainland Chinese. Clinical and Experimental Ophthalmology 40(2) 162-169. Mar, 2012.

Murakami Y, Lee BW, Duncan M, Kao A, Huang JY, Singh K, Lin SC. Racial and Ethnic Disparities in Adherence to Glaucoma Follow-Up Visits in a County Hospital Population. Archives of Ophthalmology 129(7):872-8. Jul, 2011.

Francis BA, Singh K, Lin SC, Hodapp EA, Jampel HD, Samples JR, Smith SD. Novel Glaucoma Procedures: a report by the American Academy of Ophthalmology.

Ophthalmology 118(7):1466-80. Jul, 2011.

. Singh K, Gedde SJ and the Tube versus Trabeculectomy Study Group. Interpretation and

Misinterpretation of results from the Tube Versus Trabeculectomy Study. International Ophthalmology Clinics 51(3): 141-54. 2011.

Jampel HD, Singh K, Lin SC, Chen TC, Francis BA, Hodapp E, Samples JR Smith SD. Assessment of Visual Function in Glaucoma: a report by the American Academy of Ophhalmology. Ophthalmology 118(5):986-1002. May, 2011.

Budenz DL, Barton K, Feuer WJ, Schiffman J, Costa VP, Godfrey DG, Buys YM for the Ahmed Baerveldt Comparison Study Group. Treatment Outcomes in the Ahmed Baerveldt Comparison Study After 1 Year of Follow-Up. Ophthalmology 118 (3): 443-452. March, 2011.

(30)

Page 30 of 48

Barton K, Gedde SJ, Budenz DL, Feuer WJ, Schiffman J and the Ahmed Baerveldt Comparison Study Group. The Ahmed Baerveldt Comparison Study: Methodology, Baseline Patient Characteristics, and Intraoperative Complications. Ophthalmology 118 (3): 435-442. March, 2011.

Shrivastava A and Singh K. Medical Management of Glaucoma: Principles and Practice. Indian Journal of Ophthalmology 59(1) S88-92. January, 2011.

Wang D, Singh K, Weinreb RN, Kempen J, He M, Lin S. Central Corneal Thickness and Related Factors in an Elderly American Chinese Population. Clinical and Experimental Ophthalmology 39:412-420, 2011.

Chao DL, Shrivastava A, Kim DH, Lin H, Singh K. Axial Length Does Not Correlate With Degree of Visual Field Loss in Myopic Chinese Individuals With Glaucomatous Appearing Optic Nerves. Journal of Glaucoma 19(8) 509-13. Oct-Nov, 2010.

Chang TC and Singh K. Spontaneous Venous Pulsation as a Barometer For Translaminar Pressure Fluctuation. Journal of Glaucoma 19(5):347-8. June-July, 2010.

Shrivastava A and Singh K. The Effect of Cataract Extraction on Intraocular Pressure. Current Opinion in Ophthalmology 21(2):118-122. Mar, 2010.

Gedde SJ, Heuer DK, Parrish RK 2nd; Tube Versus Trabeculectomy Study Group. Review of Results from the Tube Versus Trabeculectomy Study. Current Opinion in

Ophthalmology 21(2): 123-28. Mar, 2010.

Silva RA, Doshi A, Law SK, Singh K. Postfiltration Hypotony Maculopathy in Young Chinese Myopic Women with Glaucomatous Appearing Optic Neuropathy. Journal of Glaucoma 19(2): 105-110. February, 2010.

Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Tube Versus Trabeculectomy Study Group. Three-year Follow-Up of the Tube versus Trabeculectomy Study. American Journal of Ophthalmology 148(5):670-84. Nov, 2009.

Wilson MR, Singh K. Intraocular Pressure: Does it Measure Up? Open Ophthalmology Journal. 3:32-37. Sep 2009.

Singh K. Is the patient getting worse? Open Ophthalmology Journal. 3:65-66. Sep, 2009. Singh K and Shrivastava A. Intraocular Pressure Fluctuations: How Much Do They Matter? Current Opinion in Ophthalmology 20(2):84-7. March, 2009.

Raucher FM, Gedde SJ, Schiffman JC, Feuer WJ, Barton K and Lee RK on behalf of the Tube versus Trabeculectomy Study Group. Motility Disturbances in the Tube Versus Trabeculectomy Study During the First Year of Follow-Up. American Journal of Ophthalmology 147(3):458-66. March, 2009.

(31)

Page 31 of 48

Chang TC and Singh K. Glaucomatous Disease in Patients with Normal Pressure Hydrocephalus. Journal of Glaucoma 18(3):243-6. March, 2009.

Singh K and Shrivastava A. Early Aggressive Intraocular Pressure Lowering, Target Intraocular Pressure and a Novel Concept for Glaucoma Care. Survey of Ophthalmology 53: S33-38. Nov-Dec, 2008.

Kim HY, Egbert PR, Singh K. Long-term Comparison of Primary Trabeculectomy with 5-Fluorouracil versus Mitomycin C in West Africa. Journal of Glaucoma 17(7):578-83. Oct-Nov, 2008.

Moss MJ, Nguyen D, Liu IY, Singh K, Montague A, Egbert RP, De Kaspar MH, Ta NC. Comparison of One-Day Versus One-Hour Application of Topical Gatifloxacin in

Eliminating Conjunctival Bacterial Flora. Ophthalmology 115 (11):2013-2016. November, 2008.

Lee BW, Sathyan P, John RK, Singh K, Robin AL. Predictors of and Barriers Associated with Poor Follow-up among Glaucoma Patients in South India. Archives of

Ophthalmology 126 (10):1448-54. Oct, 2008.

Singh K. Normal Tension Glaucoma: A Different Disease? Journal of Current Glaucoma Practice 2(3): 1-3. September-December, 2008.

Ta CN, Chan I, Singh HD, Paterno J, Fisher E, Singh K, Montague A, Egbert P,

Cockerham G, and De Kaspar HM. Prospective Comparison of Topical Moxifloxacin in Eliminating Conjunctival Bacterial Flora Following a One-Day or One-Hour Application. Journal of Ocular Pharmacology and Therapeutics (4):427-31. Aug, 2008.

Minckler DS, Francis BA, Hodapp EA, Jampel HD, Lin SL, Samples JR, Smith S, and Singh K. Aqueous Shunts in Glaucoma: a report by the American Academy of

Ophthalmology. Ophthalmology 115(6): 1089-98. June, 2008.

Singh K, Lee B, Wilson MR and the Glaucoma RAND-Like Appropriateness Methodology Group. An Expert Panel Assessment of Glaucoma Therapy: Modification of Existing RAND-Like Methodology for Consensus in Ophthalmology. Part II: Results and Interpretation. American Journal of Ophthalmology 145(3) 575-581. March, 2008

Wilson MR, Lee P, Weinreb RN, Lee B, Singh K and the Glaucoma Modified RAND-Like Methodology Group. An Expert Panel Assessment of Glaucoma Therapy: Modification of Existing RAND-Like Methodology for Consensus in Ophthalmology. Part I: Methodology and Design. American Journal of Ophthalmology 145(3) 570-574. March, 2008.

Ta CN, Egbert PR, Singh K, Miño De Kaspar H. Prospective Comparative Evaluation of Povidone-Iodine (10% for 5 minutes versus 5% for 1 minute) as Prophylaxis for

Ophthalmic Surgery. Journal of Cataract and Refractive Surgery 34(1): 171-172. Jan, 2008.

(32)

Page 32 of 48

Lin SL, Singh K, Dueker DK, Fechtner RD, Minckler DS, Samples JR and Schuman JS. Optic Nerve Head and Retinal Nerve Fiber Layer Analysis. Ophthalmology 114(10): 1937-1949. October, 2007.

Dueker DK, Singh K, Fechtner RD, Lin SL, Minckler DS, Samples JR and Schuman JS. Corneal Thickness Measurement in the Management of Primary Open Angle Glaucoma. Ophthalmology 114(9): 1779-1787. September, 2007.

Singh K, Van Buskirk EM and Spaeth G. A Blink at Diagnosing Glaucoma Suggests that More May Be Less. Ophthalmology 114(7): 1239-1240. July, 2007.

Feldman RM, Tanna AP, Gross RL, Chuang AZ, Baker L, Reynolds A, Prager TC, Additivity Study Group. Comparison of the Ocular Hypotensive Efficacy of Adjunctive Brimonidine 0.15% or Brinzolamide 1% in Combination With Travoprost 0.004%. Ophthalmology 114(7): 1248-1254. July, 2007.

Singh K. Long-Term IOP Fluctuation May Not Be As Important As Previously Reported. International Glaucoma Review 9(1); June, 2007.

Thygeson J, Burk R, Carassa R, Crichton A, Goni FJ, Menage M, Miglior S, Montgomery D, Nordmann JP, Roberts T and Singh K. Criteria for Choosing Clinically Effective Glaucoma Treatment. Current Therapeutic Research 68(3) May/June 2007.

Doshi A, Kreidl KO, Lombardi L, Sakamoto D and Singh K. Nonprogressive Glaucomatous Cupping and Visual Field Abnormalities in Young Chinese Males. Ophthalmology 114(3): 472-479 March, 2007.

Doshi A and Singh K. Cost Effective Evaluation of the Glaucoma Suspect. Current Opinion in Ophthalmology 18: 97-103, 2007.

Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC and the Tube Versus Trabeculectomy Study Group. Surgical Complications in the Tube vs

Trabeculectomy Study During the First Year of Follow-Up. American Journal of Ophthalmology 143(1): 23-31. January, 2007.

Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL and the Tube Versus Trabeculectomy Study Group. Treatment Outcomes in the Tube vs Trabeculectomy Study After One Year of Follow-Up. American Journal of Ophthalmology 143(1): 9-22. January, 2007.

Wong M, Menapace R, Furlong RC, Alio J, Toyos R, Palmberg P, Singh K, and Alfonso E. Cataract Surgical Problem, Consultation Regarding Management of Inadvertant Bleb

Formation. Journal of Cataract and Refractive Surgery 32(4):550-555. April, 2006. Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD, Tube Versus Trabeculectomy Study Group. The Tube Versus Trabeculectomy Study: Design and Baseline Characteristics of Study Patients. American Journal of Ophthalmology 140(2); 275-87. August, 2005.

References

Related documents

(A,B) Pre-diabetic mice had significantly elevated glucose levels on both days 7 and 21 as compared to Control mice (*p<0.05) while treatment with BMP-7 significantly decreased

Professor of Medicine & Epidemiology Associate Director, AIDS Service Division of Infectious Diseases Johns Hopkins University School of Medicine..

This paper analyzes the effect of monetary policy uncertainty on the term structure of interest rates, the variation in conditional yield volatilities and bond risk premia.. I

Hrvatski bankarski sustav do osamostaljenja odnosno i prije samog formiranja SFR Jugoslavije prolazi kroz nekoliko kriznih situacija nakon 2. godine financijski

Johns Hopkins University Baltimore Maryland School of Medicine Johns Hopkins University Baltimore Maryland School of Public Health Johns Hopkins University Baltimore Maryland

Here the internal parameters called photocurrent, diode saturation current, series resistance, shunt resistance, diode ideality factor, and cell temperature are

And sixth, the extent of the divergence between prices and mean beliefs depends on the specific assumptions adopted about the utility function of traders, and the distribution of

Proposed new paragraph (a)3 requires that in the event services are provided to a recipient engaged in a trade or business in this State and another state(s), a